FiercePharma

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...
The Trentonian

Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR(R) (Methylnaltrexone Bromide) At ASRA’s 46th Annual Spring Meeting

RELISTOR(R) (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic ...
FierceBiotech

Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation

Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain COLLEGEVILLE, Pa. & TARRYTOWN, ...
The Trentonian

Salix Will Share RELISTOR(R) (Methylnaltrexone Bromide) Data Analysis at the 2021 American Society of Clinical Oncology Annual Meeting and 2021 Annual Meeting of the ...

RELISTOR(R) (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic ...